INGN - NASDAQ

Inogen, Inc.

INGN·NASDAQ

$5.98

-1.6%

HealthcareMedical - Devices

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$161.91M

EPS-0.8500

P/E Ratio-7.04

Earnings Date08/06/2026

298.62M

Assets

3Y-26.0%

5Y-35.0%

10Y+40.0%

106.39M

Total Liabilities

-13%

3Y-1.0%

5Y-5.0%

10Y+233.0%

192.23M

Total Equity

11%

3Y-35.0%

5Y-45.0%

10Y+6.0%

Inogen, Inc. Funding & Solvency Profile

INGN · NASDAQ

Current Assets

Cash & Cash Equivalents103.73M

Net Receivables38.86M

Inventory25.97M

Other Current Assets13.89M

Total Current Assets198 M

Non-Current Assets

Property, Plant & Equipment52.86M

Goodwill & Intangible Assets41.46M

Long-Term Investments0.00

Other Non-Current Assets6.00M

Total Non-Current Assets59 M

Total Assets

298.62M

Financial Health Analysis

Current Ratio

3.12x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.55x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

135 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

66% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Inogen, Inc. Balance Sheet

INGN • NASDAQ

Inogen, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	103.7M	113.8M	125.5M	187M	235.5M	212M	198M	196.6M	143M	92.9M	66.1M	56.8M	13.5M	15.1M	3.9M
Short-Term Investments	15.8M	0.0	3M	0.0	10M	19.3M	11.1M	43.7M	31M	21M	16.8M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	119.6M	113.8M	128.5M	187M	245.5M	231.2M	209.1M	240.3M	173.9M	113.9M	82.9M	56.8M	13.5M	15.1M	3.9M
Net Receivables	38.9M	30.1M	42.9M	64.4M	25.8M	31.8M	37.3M	39.7M	32.8M	30.8M	22M	21.5M	10.3M	7M	4.4M
Accounts Receivables	38.9M	29.6M	42.2M	62.7M	24.5M	29.7M	34.3M	37M	31.4M	30.8M	19.9M	15.7M	10.2M	7M	4.4M
Other Receivables	0.0	538K	669K	1.6M	1.3M	2M	3M	2.7M	1.3M	0.0	2.2M	5.8M	87K	0.0	0.0
Inventory	26M	24.8M	21.8M	34.1M	31.9M	24.8M	35.7M	27.1M	18.8M	14.3M	8.6M	7.6M	4.2M	4.1M	1.7M
Prepaids	0.0	0.0	0.0	0.0	26M	17.9M	10.2M	7.5M	2.6M	1.7M	870K	1.1M	289K	309K	433K
Other Current Assets	13.9M	16.7M	13.8M	19.2M	0.0	0.0	0.0	0.0	1.7M	831K	397K	5.5M	4.5M	159K	70K
Total Current Assets	198.3M	185.5M	207.1M	304.6M	329.2M	305.7M	292.2M	314.6M	228.5M	161.5M	114.8M	92.5M	32.8M	26.7M	10.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	52.9M	62.7M	70.7M	64.9M	63.8M	37.1M	25.3M	22.3M	20.1M	25.2M	30.7M	31.9M	29.7M	20.3M	12.8M
Goodwill	10.7M	9.5M	10.1M	32.9M	33M	33.2M	33M	2.3M	2.4M	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	30.8M	30.5M	34.6M	177K	60.1M	68.8M	77.5M	3.8M	4.7M	241K	229K	270K	215K	558K	793K
Goodwill & Intangible Assets	41.5M	40M	44.6M	33M	93.1M	102M	110.5M	6M	7.1M	241K	229K	270K	215K	558K	793K
Tax Assets	0.0	0.0	0.0	0.0	0.0	14.5M	14.5M	30.1M	18.6M	26.7M	15.5M	15.2M	17.9M	0.0	0.0
Other Non-Current Assets	6M	8.1M	3.8M	2.4M	3.4M	2.7M	4.9M	2.8M	765K	410K	97K	97K	1.8M	79K	52K
Total Non-Current Assets	100.3M	110.7M	119.1M	100.4M	160.3M	156.2M	155.1M	61.3M	46.6M	52.5M	46.5M	47.5M	49.6M	20.9M	13.7M
Total Assets	298.6M	296.2M	326.2M	405M	489.5M	461.9M	447.3M	375.9M	275.1M	214M	161.3M	140.1M	82.4M	47.6M	24.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	29.6M	16.8M	13.5M	18.7M	10.8M	22.8M	28.3M	23.7M	17.1M	10M	11M	11.3M	9.2M	6M	5.8M
Accounts Payable	29.4M	16.6M	13.5M	18.2M	10.3M	12.5M	16.4M	13.7M	9.5M	5.7M	7.4M	6.7M	8.8M	6M	5.7M
Other Payables	183K	142K	27K	492K	561K	10.3M	11.9M	10M	7.6M	4.3M	3.6M	4.6M	910K	25K	28K
Accrued Expenses	0.0	27.7M	27.8M	26.4M	32.3M	7.1M	6.2M	11.4M	6.9M	6.1M	5.3M	8.5M	2.9M	2.4M	0.0
Short Term Debt	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	315K	299K	5.3M	3.9M	2.5M
Capital Lease Obligations (Current)	0.0	2.8M	3.7M	3.5M	3.4M	1.9M	2M	0.0	0.0	0.0	0.0	-4.4M	0.0	0.0	0.0
Tax Payables	183K	142K	27K	492K	561K	1.2M	821K	392K	345K	281K	56K	0.0	0.0	25K	21K
Deferred Revenue	5.5M	6.7M	8M	8.9M	8.6M	7M	5.5M	4.5M	3.5M	2.2M	2.3M	2.3M	1.5M	1.1M	594K
Other Current Liabilities	25.2M	22.7M	19.6M	7.8M	6.5M	17.9M	8.1M	7M	6.3M	4.5M	3.1M	-3.6M	809K	457K	250K
Total Current Liabilities	63.5M	76.7M	72.5M	65.3M	61.5M	56.7M	50.2M	46.6M	33.9M	22.8M	22M	18.7M	19.7M	13.8M	9.1M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	315K	5.4M	5.1M	7.1M
Deferred Revenue (Non-Current)	3.6M	5.7M	8.2M	10.4M	11.9M	11.8M	13.5M	11.8M	9.4M	7M	4.2M	2.2M	776K	0.0	0.0
Deferred Tax Liabilities (Non-Current)	6.7M	6.9M	8.5M	0.0	0.0	25K	87K	232K	348K	0.0	0.0	334K	9.8M	0.0	0.0
Other Non-Current Liabilities	18.2M	16.4M	13.9M	12.1M	22.6M	35.6M	34.2M	6.8M	4.4M	2.1M	1.1M	709K	260K	164K	337K
Total Non-Current Liabilities	42.9M	45.6M	48.9M	42.3M	57.8M	55.5M	52.5M	18.9M	14.1M	9.1M	5.3M	3.2M	6.4M	5.2M	7.4M
Capital Lease Obligations	14.3M	19.4M	21.9M	23.3M	26.7M	10M	6.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	106.4M	122.3M	121.4M	107.6M	119.3M	112.2M	102.7M	65.5M	48M	32M	27.3M	21.9M	26.1M	19M	16.6M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	140.1M	118.9M	109.6M	83.4M
Common Stock	27K	24K	23K	23K	23K	22K	22K	22K	21K	20K	20K	19K	1K	1K	1K
Additional Paid-In Capital	363.5M	328.2M	320.5M	312.1M	299.5M	273.5M	263.3M	249.2M	218.1M	194.5M	179.1M	174.8M	0.0	0.0	0.0
Retained Earnings	-175.6M	-152.8M	-116.9M	-14.5M	69.3M	75.6M	81.4M	60.5M	8.6M	-12.4M	-45.1M	-56.7M	-62.6M	-81M	-75.8M
Accumulated Other Comprehensive Income/Loss	4.2M	-1.5M	1.2M	-243K	1.5M	475K	-87K	724K	272K	-35K	-37K	-25.8M	-16M	-10.6M	-6.1M
Total Stockholders' Equity	192.2M	173.9M	204.8M	297.4M	370.2M	349.6M	344.6M	310.4M	227M	182.1M	134M	118.2M	56.3M	28.6M	7.6M
Total Equity	192.2M	173.9M	204.8M	297.4M	370.2M	349.6M	344.6M	310.4M	227M	182.1M	134M	118.2M	56.3M	28.6M	7.6M
SUMMARY
Total Liabilities & Equity	298.6M	296.2M	326.2M	405M	489.5M	461.9M	447.3M	375.9M	275.1M	214M	161.3M	140.1M	82.4M	47.6M	24.1M
Total Investments	15.8M	0.0	3M	0.0	10M	19.3M	11.1M	43.7M	31M	21M	16.8M	0.0	0.0	0.0	0.0
Total Debt	17.5M	19.4M	21.9M	23.3M	26.7M	10M	6.7M	0.0	0.0	0.0	315K	614K	10.6M	8.9M	9.6M
Net Debt	-86.3M	-94.4M	-103.6M	-163.7M	-208.9M	-202M	-191.3M	-196.6M	-143M	-92.9M	-65.8M	-56.2M	-2.9M	-6.2M	5.7M
Shares Outstanding	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390	27,040,390

SEC Filings

INGN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 06, 2026	April 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 24, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing

Showing 1 to 10 of 212 filings

Related Guides

Blog Categories

Continue your INGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.